Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis.

导出 LinkOut

翻译打印收藏纠错

第一作者： Andreas,Reiter

第一单位： Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.

作者： Andreas,Reiter ^[1] ; Juliana,Schwaab ^[1] ; Daniel J,DeAngelo ^[2] ; Jason,Gotlib ^[3] ; Michael W,Deininger ^[4] ; Kristen M,Pettit ^[5] ; Iván,Alvarez-Twose ^[6] ; Alessandro M,Vannucchi ^[7] ; Jens,Panse ^[8] ; Uwe,Platzbecker ^[9] ; Olivier,Hermine ^[10] ; Ingunn,Dybedal ^[11] ; Hui-Min,Lin ^[12] ; Svetlana N,Rylova ^[13] ; Katrin,Ehlert ^[14] ; Saša,Dimitrijević ^[13] ; Deepti H,Radia ^[15]

作者单位： Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany. ^[1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. ^[2] Division of Hematology, Stanford Cancer Institute/Stanford University School of Medicine, Stanford, CA. ^[3] Versiti Blood Research Institute and Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI. ^[4] Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI. ^[5] Institute of Mastocytosis Studies of Castilla-La Mancha (CLMast) and Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Spanish Reference Center of Mastocytosis, Toledo, Spain. ^[6] Center for Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy. ^[7] Department of Oncology, Hematology, Hemostaseology, and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany. ^[8] Clinic and Polyclinic for Hematology, Cell Therapy and Hemostaseology, Leipzig University, Leipzig, Germany. ^[9] Department of Hematology, Rare Diseases Reference Center for Mastocytoses (CEREMAST), Assistance Publique-Hôpitaux de Paris (APHP)-Necker-Enfants Malades Hospital, and Imagine Institute-INSERM U1163, Paris University, Paris, France. ^[10] Department of Hematology, Oslo University Hospital, Oslo, Norway. ^[11] Blueprint Medicines Corporation, Cambridge, MA. ^[12] Blueprint Medicines International (Switzerland), Zug, Switzerland. ^[13] Blueprint Medicines (Germany) GmbH, Munich, Germany. ^[14] Guy's &amp; St Thomas's NHS Foundation Trust, London, United Kingdom. ^[15]

主题词成年人(Adult);人类(Humans);肥大细胞增生症, 系统性(Mastocytosis, Systemic);原癌基因蛋白质类c-kit(Proto-Oncogene Proteins c-kit);吡唑类(Pyrazoles);吡咯类(Pyrroles)

DOI 10.1182/bloodadvances.2022007539

PMID 35640224

发布时间 2022-11-15

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Blood advances

2022年6卷21期

5750-5762页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis.

Blood advances

相似文献

Blood advances

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis.

Blood advances

相似文献

Blood advances

相关期刊

检索历史清除